• O. Benkert


Antipsychotika sind eine chemisch heterogene Gruppe von Pharmaka mit antipsychotischem Wirksamkeitsschwerpunkt und unterschiedlichem NW-Profil. Der häufig synonym verwendete Begriff »Neuroleptikum« wird international weitgehend durch den Begriff Antipsychotikum ersetzt.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andreasen NC, Liu D, Ziebell S et al (2013) Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013 170(6):609–615PubMedCrossRefGoogle Scholar
  2. Barnes TR, Paton C (2011) Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 25(5):383–399PubMedCrossRefGoogle Scholar
  3. Choi KH, Wykes T, Kurtz MM (2013) Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry 203:172–178PubMedCentralPubMedCrossRefGoogle Scholar
  4. Declercq T, Petrovic M, Azermai M et al (2013) Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev 3:CD007726Google Scholar
  5. DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde) (Hrsg) (2006) Behandlungsleitlinie Schizophrenie. Reihe: S3 Praxisleitlinien in Psychiatrie und Psychotherapie, Bd 1. Springer, Berlin Heidelberg New YorkGoogle Scholar
  6. DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (2012) S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression; Langfassung Version 1.3. Januar, basierend auf der Fassung von November 2009. AWMF- Register-Nr. nvl-005Google Scholar
  7. Dold M, Li C, Gillies D, Leucht S (2013) Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 23:1023–1033PubMedCrossRefGoogle Scholar
  8. Fan Z, Wu Y, Shen J et al (2013) Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res 47:1549–1556PubMedCrossRefGoogle Scholar
  9. Farahani A, Correll CU (2012) Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry 73(4):486–496PubMedCrossRefGoogle Scholar
  10. Gallego JA, Bonetti J, Zhang J et al (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138:18–28PubMedCentralPubMedCrossRefGoogle Scholar
  11. Gareri P, De Fazio P, Manfredi VG et al (2014) Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol 34(1):109–123PubMedCrossRefGoogle Scholar
  12. Harrow M, Jobe TH (2013) Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull 39(5):962–965PubMedCentralPubMedCrossRefGoogle Scholar
  13. Hsieh PH, Hsiao FY, Gau SS, Gau CS (2013) Use of antipsychotics and risk of cerebrovascular events in schizophrenic patients: a nested case-control study. J Clin Psychopharmacol 33(3):299–305CrossRefGoogle Scholar
  14. Jarskog LF, Hamer RM, Catellier DJ (2013) Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 170(9):1032–1040PubMedCrossRefGoogle Scholar
  15. Jauhar S, McKenna PJ, Radua J et al (2014) Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 204:20–29PubMedCrossRefGoogle Scholar
  16. Kales HC, Kim HM, Zivin K et al (2012) Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry169(1): 71–79Google Scholar
  17. Kane JM, Kishimoto T, Correll CU (2013) Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 12:216–226PubMedCentralPubMedCrossRefGoogle Scholar
  18. Kelly TM, Daley DC, Douaihy AB (2012) Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 37(1):11–24PubMedCentralPubMedCrossRefGoogle Scholar
  19. Khan A, Faucett J, Morrison S et al (2013) Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/ hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry 70(10):1091–1099PubMedCrossRefGoogle Scholar
  20. Kishimoto T, Agarwal V, Kishi T et al (2013a) Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 18(1):53–66CrossRefGoogle Scholar
  21. Kishimoto T, Nitta M, Borenstein M et al (2013b) Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74(10):957–965CrossRefGoogle Scholar
  22. Kishimoto T, Robenzadeh A, Leucht C et al (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 40:192–213PubMedCrossRefGoogle Scholar
  23. Klosterkötter J (2013) Prävention psychotischer Störungen. Nervenarzt 84(11):1299–1309PubMedCrossRefGoogle Scholar
  24. Kristensen D, Hageman I, Bauer J et al (2013) Antipsychotic polypharmacy in a treatment- refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy. JECT 29:271–276PubMedCrossRefGoogle Scholar
  25. Leucht C, Heres S, Kane JM et al (2011) Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127(1–3):83–92PubMedCrossRefGoogle Scholar
  26. Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962CrossRefGoogle Scholar
  27. Leucht S, Samara M, Heres S et al (2014) Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40(2): 314-326Google Scholar
  28. Lopez OL, Becker JT, Chang YF et al (2013) The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry 170(9): 1051-1058Google Scholar
  29. Maayan L, Vakhrusheva J, Correll CU (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35(7):1520-1530Google Scholar
  30. Mahmood S, Booker I, Huang J, Coleman CI (2013) Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 33: 90-94Google Scholar
  31. Nielsen J, Damkier P, Lublin H et al (2011) Optimizing clozapine treatment. Acta Psychiatr Scand 123:411–422PubMedCrossRefGoogle Scholar
  32. Nielsen J, Correll CU, Manu P et al (2013) Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry 74:603–613PubMedCrossRefGoogle Scholar
  33. Osser DN, Roudsari MJ, Manschreck T (2013) The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry 21:18–40PubMedCrossRefGoogle Scholar
  34. Porcelli S, Balzarro B, Serretti A (2012) Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 22(3):165–182PubMedCrossRefGoogle Scholar
  35. Schennach R, Riesbeck M, Mayr A et al (2013) Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients? Acta Psychiatr Scand 127:474–481PubMedCrossRefGoogle Scholar
  36. Sommer IE, Begemann MJ, Temmerman A et al (2012) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 38:1003–1011PubMedCentralPubMedCrossRefGoogle Scholar
  37. Steinert T, Baier H, Fröscher W, Jandl M (2011) Epileptische Anfälle unter der Behandlung mit Antidepressiva und Neuroleptika. Fortschr Neurol Psychiatr 79(3):138–143PubMedCrossRefGoogle Scholar
  38. Taylor DM, Smith L, Gee SH et al (2012) Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand 125:15–24PubMedCrossRefGoogle Scholar
  39. Tiihonen J, Suokas JT, Suvisaari JM et al (2012) Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 69:476–483PubMedCrossRefGoogle Scholar
  40. Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsades de Pointes. Dtsch Arztebl Int 108(41):687–693PubMedCentralPubMedGoogle Scholar
  41. Wolter DK (2009) Risiken von Antipsychotika im Alter, speziell bei Demenzen. Z Geronto-psychol -psychiatrie 22(1): 17–56Google Scholar
  42. Wu CS, Wang SC, Gau SS et al (2013) Association of stroke with the receptor-binding profiles of antipsychotics-a case-crossover study. Biol Psychiatry 73(5):414–421PubMedCrossRefGoogle Scholar
  43. Wunderink L, Nieboer RM, Wiersma D et al (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70(9):913–920PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • O. Benkert
    • 1
  1. 1.Mainz

Personalised recommendations